Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Two Nuclear Medicine focused advisory boards have been formed to provide expertise and strategic guidance to Actinium
Meeting with Iomab-B and Actimab investigators to be held to provide trial updates and discuss outlook for clinical development
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), today highlighted the Company’s activities at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting that is being held in Philadelphia, Pennsylvania June 23 – 26, 2018. The SNMMI Annual Meeting brings together leading nuclear medicine physicians, scientists, and technologists from the world’s top medical and academic institutions.
Actinium’s newly formed advisory boards will be comprised of thought leading nuclear medicine physicians and nuclear medicine technologists, respectively. These nuclear medicine advisory boards will provide expertise and strategic guidance to the Company, which Actinium will utilize to optimize their clinical and commercial efforts. In addition, Actinium will host a meeting with physicians and nuclear medicine professionals from Iomab-B and Actimab-A trial sites attending SNMMI to provide updates and discuss the progress of these programs.
Dr. Mark Berger, Actinium’s Chief Medical Officer said, “SNMMI is a particularly important meeting for Actinium and I am thrilled with our level of engagement with the nuclear medicine community this year. I am also excited by our formation of two nuclear medicine advisory boards and look forward to working with our members. We have gained many insights from physicians, scientists, and technicians that will be of great benefit to our Iomab-B and Actimab programs. Finally, it is highly motivating to meet with the investigators from our trial sites and hear their enthusiasm for our trials and passion for advancing patient outcomes through targeted conditioning for bone marrow transplant and treatment of hematologic diseases with significant unmet needs.
Representatives from Actinium’s clinical development, manufacturing and supply chain, research and development, corporate development, commercial and executive teams attended the SNMMI Annual Meeting.
Sandesh Seth, Actinium’s Chairman and CEO said, “Over the last year, infusions of key talent and a commitment to hard work allowed us to make this year’s SNMMI a particularly valuable event for Actinium. With Iomab-B making great strides in its pivotal Phase 3 trial and continued expansion of our best-in-class CD33 program we are increasingly focused on transforming our exoskeleton of a commercial supply chain to a leading, fully-integrated commercial supply chain that is supplying important therapies to the leading medical centers throughout the U.S. SNMMI provides us with key insights and interactions that will allow us to achieve this important business objective. We look forward to building on the momentum we create at the annual meeting as we work to build an independent, self-sustaining Company focused on targeted conditioning for bone marrow transplant.”
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. The Company’s targeted Antibody Radio-Conjugates (ARCs), combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies.
Iomab-B, Actinium’s lead product candidate, is currently enrolling patients in a pivotal Phase 3 trial. Iomab-B combines the anti-CD45 monoclonal antibody BC8 labeled with iodine-131 and is designed to condition the bone marrow prior to a bone marrow transplant without the need for intense chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) of age 55 or older. Actinium’s pipeline also includes a potentially best-in-class CD33 program with our ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in Phase 2 and Phase 1 clinical trials for patients with AML, myelodysplastic syndrome (MDS) and multiple myeloma.
Actinium is also developing its proprietary Actinium Warhead Enabling (AWE) technology platform to utilize the highly differentiated radioisotope actinium-225 with a wide range of targets. AWE is being utilized in a collaborative research partnership with Astellas Pharma, Inc.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Actinium Pharmaceuticals, Inc.
Principal Financial Officer
Marek Ciszewski, J.D.
Released June 25, 2018